CN208717302U - For capturing the enrichment isolation mechanism of target cell or biomolecule - Google Patents
For capturing the enrichment isolation mechanism of target cell or biomolecule Download PDFInfo
- Publication number
- CN208717302U CN208717302U CN201820848148.4U CN201820848148U CN208717302U CN 208717302 U CN208717302 U CN 208717302U CN 201820848148 U CN201820848148 U CN 201820848148U CN 208717302 U CN208717302 U CN 208717302U
- Authority
- CN
- China
- Prior art keywords
- pore channel
- reticulated matrix
- catches
- matrix
- reticulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The utility model relates to a kind of for capturing the enrichment isolation mechanism of target cell or biomolecule, including multiple multi-pore channel reticulated matrix disposed in parallel, multi-pore channel reticulated matrix includes the reticulated matrix formed by the cable of a plurality of setting that intersects, the multiple sieve pores formed by the cable of a plurality of setting that intersects and the trapping layer being fixedly attached on reticulated matrix, trapping layer includes the catches that can be specifically bound with target cell or biomolecule, and the catches at least two layers of multi-pore channel reticulated matrix is different.The utility model can combine with identical target molecule or cell-specific by the way that different catches is arranged on different layers porous structure, increase the specificity of multi-pore channel reticulated matrix, reduce the possibility of false negative and false positive；Or fix different catches on different multi-pore channel reticulated matrix and combined from different molecule or cell-specific, improve the disposable working efficiency of enrichment mechanism and application range.
Description
Technical field
The utility model relates to a kind of for capturing the enrichment isolation mechanism of target cell or biomolecule.
Background technique
In the detection of blood and biological sample, usually examined for rare cell, the rare molecule in detection sample
Being successfully separated, being enriched with for survey, these rare objects or molecule is that can detection accurately crucial.Such as in human being's production and life
In work, the test object in body fluid, food and natural environment to people is needed to detect, such as pacified in medical practice, food
Entirely, often need to detect cell (such as circulating tumor cell, erythroblast) in environmental monitoring；Microorganism is (such as medical treatment detection human body
Streptococcus pneumonia, Legionella, fungi and special pathogen such as mycoplasma, Chlamydia, Richettsia, conveyor screw, virus in liquid
Deng；The microorganism detected in field of food safety such as coliform, pathogenic bacteria (including salmonella, Shigella, golden yellow Portugal
Grape coccus, pathogenic streptococcus etc.), (tangerine of the aspergillus flavus of such as aspergillus, aspergillus parasiticus, Penicillium is green for mould and its toxin
Mould, Penicillium islandicum etc., the beading reaping hook of fusarium is mould, cereal reaping hook is mould etc.), other microorganisms further include disease in food safety
Malicious (such as hepatitis virus, swine fever virus, newcastle disease virus, horse root of Dahurian angelica kirschner virus, foot and mouth disease virus, hydrophobin, pig bubble
Virus etc.), in addition in food safety detection, helminth also by many scholars be classified as Micro biological Tests index (such as trichina,
Cysticercus)).In addition to this, certain protein, nucleic acid etc. are also often as test object, such as clinically common early diagnosis
Marker screening and gene diagnosis etc..Different test objects is needed to apply different detection method and detection platform, by
Very low in the concentration of part test object, this proposes very high requirement to detection method.
By taking erythroblast detects as an example, erythroblast cannot be seen in normal adult's peripheral blood, birth 1 week it
Visible a small amount of erythroblast in interior newborn's peripheral blood.Occurring erythroblast in adult peripheral blood, to belong to pathology existing
As erythroblast is related to hyperplastic anemia, erythremic myelosis, extramedullary hematopoiesis, other such as metastatic carcinoma of bone marrow, severe depletion of oxygen.?
In detection project in production and life, a kind of highly sensitive, at low cost, quick detection method and platform are needed.
By taking circulating tumor cell detects as an example, tumour cell in circulating tumor cell, that is, blood circulation is considered and swells
, there is relationship in the problems such as far-end transfer of tumor.Only 1-10 circulating tumor cell, catches in the 10ml blood of general cancer patient
It obtains speed slowly or poor specificity is quick detection patient's blood sample problem in the urgent need to address.Inspection for circulating tumor cell
In survey, high sensitivity, high accuracy, quick detection method and detection platform are needed.
The utility model for cell or target molecule in biological sample enrichment, using micro-fluidic enrichment mechanism technology,
Different a plurality of types of test objects such as cell, albumen, nucleic acid, microorganism (including virus and bacterium) can be carried out quick
Detection, is specifically described below.
Separately the invention CN 107338184A similar with the utility model discloses a kind of for capturing in cell or solution
The capture sieve and device of biomolecule, capture mechanism include the capture sieve of at least one or more stacking, and acquisition equipment includes tool
There is the main body of entrance, first outlet and the cavity between entrance and first outlet, capture mechanism is fixed in the cavity, entrance
It is connected to first outlet and cavity.The trapping layer for including reticulated matrix and being formed on reticulated matrix is sieved in capture, and trapping layer includes
The catches that can be specifically bound with target cell or biomolecule.Capture sieve and device in the patent have high specific
And high throughput, and the biomolecule being suitable in the molecule trapping cell by being expressed by cell or capture solution, particularly suitable for capture
With sorting circulating tumor cell.But it due to only having a kind of catches on the capture sieve in the patent, can only disposably sieve
A possibility that selecting cell, false negative and false positive occur is higher, in addition, if in solution to be detected containing plurality of target cell or
Biomolecule, it is necessary to separately repeatedly be screened, the working efficiency sieved using the capture is relatively low.The utility model patent
Selection can be used for above-mentioned different types of a variety of test objects using multilayer enrichment mechanism and a variety of catches, thus this is practical
Novel and foregoing invention has apparent difference, has original creativity.
Utility model content
The technical problem to be solved by the present invention is to provide the capture rate of a kind of pair of target cell or biomolecule is high
Enrichment isolation mechanism, the enrichment isolation mechanism can utilize different catches and identical target molecule or cell-specific
In conjunction with either through different catches in conjunction with target molecule or cell-specific not of the same race.
In order to solve the above-mentioned technical problem, a kind of technical solution that the utility model uses is:
It is a kind of for capturing the enrichment isolation mechanism of target cell or biomolecule, including multiple multi-pore channels disposed in parallel
Reticulated matrix, the multi-pore channel reticulated matrix include the reticulated matrix formed by the cable of a plurality of setting that intersects, by institute
The multiple sieve pores and the capture being fixedly attached on the reticulated matrix that the cable for a plurality of setting that intersects stated is formed
Layer, the trapping layer includes the catches that can be specifically bound with target cell or biomolecule, at least described in two layers
Catches on multi-pore channel reticulated matrix is different.
Preferably, the catches in the enrichment isolation mechanism on multi-pore channel reticulated matrix described at least three layers is not
Together；It is further preferred that the catches in the enrichment isolation mechanism on multi-pore channel reticulated matrix described at least four layers is not
Together.Most preferably, the catches on multi-pore channel reticulated matrix described in every layer is different.
According to an embodiment, in the enrichment isolation mechanism on multi-pore channel reticulated matrix described at least two layers
Catches is specifically bound with same target cell or biomolecule respectively, so that the enrichment isolation mechanism is caught
Specific raising is obtained, false negative and false positive are reduced, further increased to the capture rate of this kind of target cell or biomolecule.
Preferably, the catches on multi-pore channel reticulated matrix described at least three layers respectively with same target cell or life
Object molecular specificity combines；It is further preferred that catches on multi-pore channel reticulated matrix described at least four layers respectively with
Same target cell or biomolecule specific binding；Most preferably, catching on multi-pore channel reticulated matrix described in every layer
Object is obtained to specifically bind with same target cell or biomolecule respectively.
According to a kind of embodiment, at least one multi-pore channel reticulated matrix of multiple multi-pore channel reticulated matrix is caught
Obtain object and a kind of target cell or biomolecule specifically bound, the catches of at least another multi-pore channel reticulated matrix with it is another
Kind target cell or biomolecule specific binding, so that removing each multi-pore channel reticulated matrix after screening
Afterwards, the target cell or biomolecule on each multi-pore channel reticulated matrix can be separated, disposably screens multiple mesh to realize
Cell or biomolecule are marked, the working efficiency and application range of enrichment mechanism are improved.
Preferably, the catches of at least three multi-pore channel reticulated matrix is directed to three kinds of different target cells or biology respectively
Molecule.It is further preferred that the catches of at least four multi-pore channel reticulated matrix be directed to respectively four kinds of different target cells or
Biomolecule.It is further preferable that the catches of at least five multi-pore channel reticulated matrix is directed to five kinds of different target cells respectively
Or biomolecule.Most preferably, the catches of each multi-pore channel reticulated matrix respectively from different target cells or life
Object molecular specificity combines.
Specifically, the catches is the specific antibody or other kinds of spy for target cell or target molecule
Opposite sex identification molecule, the target molecule that the catches is directed to are selected from one of following multiple types or a variety of::
EpCAM, EphB4, EGFR, HER2, HER-2/neu, MUC-1, folacin receptor, AFP, CEA, Cyfra21-1, TPA, TPS,
NMP22, β 2-MG, thyroglobulin, ferritin, CA19-9, CA125, CA50, CA72-4, CA242, CA15-3, SCC,
LDH, NSE, PSA, ER, progesterone receptor, HCG, β-hCG, prolactin, ACTH, calcitonin, ras gene, P53, myc- gene,
DHEA-S, cortisol, aldosterone, uPA/PAI-1, serotonin, 5-hydroxyindoleacetic acid, HGH, FSH, LH, TSH, paraprotein, chest
Gland pyrimidine kinases, neopterin, SEA, Protein S -100, M2-PK, Chromogranin A, bone-specific alkaline phosphatase, deoxidation pyridine
Quinoline, CASA, adrenaline substance, catecholamine, homovanillic acid, adrenin, vanillylmandelic acid (VMA), f-PSA, PCA3,
AFP, P-ALP, calcitonin, gastrin, TSA, AFU, γ GT, ALP, CA549, PAP, bence-Jones protein.
Specifically, the catches is bonded on the reticulated matrix by physical absorption and/or chemical bonded refractory.
Preferably, the catches is by using traut ' s reagent or the mercaptan molecules of salt with biotin-avidin
It is connected on the reticulated matrix.
Specifically, the mesh portion of multi-pore channel reticulated matrix described in adjacent two layers is arranged in a staggered manner.
The mesh portion of adjacent two layers multi-pore channel reticulated matrix in the utility model, which is arranged in a staggered manner, refers to one layer of multi-pore channel
The mesh portion of reticulated matrix is blocked by the cable of another layer of multi-pore channel reticulated matrix, i.e. the top view from the enrichment isolation mechanism
From the point of view of, multiple multi-pore channel reticulated matrix are not exclusively overlapped.
Specifically, in multi-pore channel reticulated matrix described in adjacent two layers lower layer's multi-pore channel reticulated matrix with respect to upper layer multi-pore channel
Reticulated matrix rotates 5~180 °.
Preferably, in multi-pore channel reticulated matrix described in adjacent two layers lower layer's multi-pore channel reticulated matrix with respect to upper layer multi-pore channel
Reticulated matrix rotates 10~90 °.
It is further preferred that lower layer's multi-pore channel reticulated matrix is with respect to upper layer in multi-pore channel reticulated matrix described in adjacent two layers
Multi-pore channel reticulated matrix rotates 30~60 °.It is further preferred that each multi-pore channel reticulated matrix is with respect to upper layer multi-pore channel
The direction of rotation of reticulated matrix is consistent.
Direction of rotation in the utility model unanimously refers to each multi-pore channel reticulated matrix with respect to the netted base of upper layer multi-pore channel
Body can be rotated clockwise or be rotated counterclockwise.Along perpendicular on the direction of multi-pore channel reticulated matrix plane, upper layer is N layers,
Lower layer is N+1 layers, when N+1 layers of multi-pore channel reticulated matrix are to rotate clockwise relative to n-th layer multi-pore channel reticulated matrix, then
All multi-pore channel reticulated matrix are to rotate clockwise relative to upper layer multi-pore channel reticulated matrix in acquisition equipment；As N+1
It is when layer multi-pore channel reticulated matrix relative to n-th layer multi-pore channel reticulated matrix is rotation counterclockwise, then all more in acquisition equipment
Duct reticulated matrix is rotation counterclockwise relative to upper layer multi-pore channel reticulated matrix.N in the utility model is the number of plies.
It is further preferred that rotation angle of each multi-pore channel reticulated matrix relative to upper layer multi-pore channel reticulated matrix
It is identical.
The rotation angle of the utility model refers to multi-pore channel reticulated matrix relative to upper layer multi-pore channel reticulated matrix with porous
The center of road reticulated matrix is axle center, the angle rotated clockwise or counter-clockwise；Rotation angle it is identical refer to N+2 layers it is porous
The angle that road reticulated matrix is rotated relative to N+1 layers of multi-pore channel reticulated matrix and N+1 layers of multi-pore channel reticulated matrix relative to
The angle of n-th layer multi-pore channel reticulated matrix rotation is identical.
The rugosity of cable refers in the utility model, the width of cable in the top view of multi-pore channel reticulated matrix；Specifically,
The rugosity of the cable is 10 μm~500 μm；Preferably, the rugosity of the cable is 20 μm~200 μm；Further preferably
Ground, the rugosity of the cable are 20~50 μm；It is highly preferred that the rugosity of the cable is 40~50 μm.
The thickness of cable refers in the utility model, the distance between the upper and lower surface of multi-pore channel reticulated matrix；Specifically,
The cable with a thickness of 10 μm~500 μm；Preferably, the cable with a thickness of 20 μm~200 μm；Further preferably
Ground, the cable with a thickness of 20~50 μm；It is highly preferred that the cable with a thickness of 40~50 μm.
Specifically, the cross-sectional area of the sieve pore is 10~6000 μm2；Preferably, the cross section of the sieve pore
Area is 20~3000 μm2；It is further preferred that the cross-sectional area of the sieve pore is 700~3000 μm2；It is more highly preferred to
Ground, the cross-sectional area of the sieve pore are 700~2000 μm2
The spacing of adjacent two layers multi-pore channel reticulated matrix refers to that the lower surface of upper layer multi-pore channel reticulated matrix is porous to lower layer
The distance between the upper surface of road reticulated matrix；Specifically, the spacing of multi-pore channel reticulated matrix described in adjacent two layers be 0.1~
10mm, it is preferable that the spacing of multi-pore channel reticulated matrix described in adjacent two layers is 0.5~1.5mm.
Specifically, the number of the multi-pore channel reticulated matrix is 2~30, it is preferable that the netted base of the multi-pore channel
The number of body is 5~10.
Specifically, the shape of the cross section of the sieve pore is square, rectangle, triangle, polygon, circle, puts down
It is row quadrangle, trapezoidal one or more.
Preferably, the polygon is the closed figure formed by five or more sides.
The enrichment isolation mechanism of the utility model further includes having entrance, first outlet and positioned at the entrance and described
First outlet between cavity main body, multiple multi-pore channel reticulated matrix are fixed in the cavity, described
Entrance and the first outlet are connected with the cavity.The main body is preferably using existing manufacturing technology as being molded
Forming technique manufacture.The material of main body should compatible solvent.For example, PEEK meets above-mentioned condition.
Preferably, the cavity is divided into the first cavity and the second cavity two by multiple multi-pore channel reticulated matrix
A part.
It is further preferred that the multi-pore channel reticulated matrix is horizontally disposed, the entrance is located at the enrichment and sieves
It selects the top of mechanism and is communicated with first cavity, the first outlet is located at the lower section of the enrichment isolation mechanism
And it is communicated with second cavity.
It is further preferred that the central axis of the entrance and the first outlet is netted in the multi-pore channel
Plane locating for matrix.
Preferably, the main body further has second outlet, be formed in the main body and with the cavity
And the microfluidic channel for being used to collect captured cell or biomolecule that the second outlet communicates.
Preferably, the enrichment isolation mechanism further comprises being set in the microfluidic channel to be used for quilt
The counting mechanism that the cell or biomolecule of capture are counted.
It is further preferred that the counting mechanism includes impedance measurement electrode.
The scope of the utility model, however it is not limited to technical solution made of the specific combination of above-mentioned technical characteristic, while
The other technical solutions for being carried out any combination by above-mentioned technical characteristic or its equivalent feature and being formed should be covered.Such as features described above
The technical solution that with (but being not limited to) disclosed herein there is the technical characteristic of similar functions to be replaced mutually and formed
Deng.
Since above-mentioned technical proposal is used, the utility model has the advantage that compared with prior art
It, can be with identical target molecule or cell by the way that different catches is arranged on different multi-pore channel reticulated matrix
Specific binding, increases the specificity of enrichment isolation mechanism, reduces the possibility of false negative and false positive；Or it different catches
Object is obtained with target molecule not of the same race in conjunction with cell-specific, improves the working efficiency and application range of enrichment mechanism, mention
High capture rate.
Detailed description of the invention
Attached drawing 1 is the structural schematic diagram of the utility model；
Attached drawing 2 is the explosive view of the utility model；
Attached drawing 3 is the first partial enlarged drawing of attached drawing 2；
Attached drawing 4 is the second partial enlarged view of attached drawing 2；
Attached drawing 5 is showing for the multi-pore channel reticulated matrix with captured target cell or biomolecule of the utility model
It is intended to；
Attached drawing 6 is the schematic diagram for the multi-pore channel reticulated matrix that the mesh portion of the utility model is arranged in a staggered manner.
Wherein: 11, entrance；12, first outlet；20, multi-pore channel reticulated matrix；21, catches；22, sieve pore；23, cable；
3, captured target cell or biomolecule.
Specific embodiment
It is a kind of for capture the enrichment isolation mechanism of target cell or biomolecule, including main body, cavity, counting mechanism with
And multiple multi-pore channel reticulated matrix 20.Main body includes entrance 11, first outlet 12, second outlet, microfluidic channel.Main body is preferred
It is manufactured using existing manufacturing technology such as injection molded technology.The material of main body should compatible solvent.For example, PEEK meet it is above-mentioned
Condition.Microfluidic channel communicates with cavity and second outlet and for collecting captured target cell or biomolecule 3.
As shown in Fig. 1, entrance 11 is located at the top of multiple multi-pore channel reticulated matrix 20, and first outlet 12 is located at multiple more
The lower section of duct reticulated matrix 20.Preferably, entrance 11 and the central axis of first outlet 12 are in multi-pore channel reticulated matrix 20
Locating plane.
Cavity is between entrance 11 and first outlet 12, and multiple multi-pore channel reticulated matrix 20 are fixed in the cavity, entrance
11 are connected with first outlet 12 with cavity.Preferably, cavity by multiple multi-pore channel reticulated matrix 20 be divided into the first cavity and
Second part of cavity two.Entrance 11 is connected with the first cavity, and first outlet 12 is connected with the second cavity.
Counting mechanism is set in microfluidic channel and based on carrying out to captured target cell or biomolecule 3
Number.Preferably, counting mechanism includes impedance measurement electrode.
As shown in Fig. 2, multiple multi-pore channel reticulated matrix 20 are arranged in parallel.In the utility model, multi-pore channel reticulated matrix
20 number is 2~30, preferably 5~10.
Multi-pore channel reticulated matrix 20 includes the reticulated matrix formed by the cable 23 of a plurality of setting that intersects, by a plurality of phase
The multiple sieve pores 22 and the trapping layer being fixedly attached on reticulated matrix that mutually cable 23 arranged in a crossed manner is formed.
In order to specifically bind with target cell or biomolecule 3, trapping layer includes can be with target cell or life
The catches 21 that object molecule 3 is specifically bound.Specifically, catches 21 is bonded to netted by physical absorption and/or chemical bonded refractory
On matrix.Preferably, catches 21 is connected by using traut ' s reagent or the mercaptan molecules of salt with biotin-avidin
To reticulated matrix.
Target cell or biomolecule 3 in the present embodiment are circulating tumor cell (CTCs), hereinafter referred to as CTCs.
In the case where in order to can guarantee high throughput while improving capture rate, increase target cell or biomolecule 3 with it is porous
The contact probability of road reticulated matrix 20.22 part of sieve pore of adjacent two layers multi-pore channel reticulated matrix 20 is arranged in a staggered manner.
Following emphasis illustrates how to realize that 22 part of sieve pore is arranged in a staggered manner.As shown in attached drawing 2,3,6, with adjacent porous road net
The center of shape matrix 20 is rotation center, the normal direction of Plane of rotation perpendicular to multi-pore channel reticulated matrix 20 plane, it is adjacent
Upper layer multi-pore channel reticulated matrix 20 and the multi-pore channel reticulated matrix 20 of lower layer between have rotation angle [alpha].Adjacent two layers multi-pore channel
In reticulated matrix 20 lower layer's multi-pore channel reticulated matrix 20 relative to upper layer multi-pore channel reticulated matrix 20 rotate 5~180 °, i.e. α be 5~
180°；Preferably, α is 10~90 °, it is further preferred that α is 30~60 °.
Further, the direction of rotation of the opposite upper layer multi-pore channel reticulated matrix 20 of each multi-pore channel reticulated matrix 20 is consistent.
Further, each multi-pore channel reticulated matrix 20 is identical relative to the rotation angle of upper layer multi-pore channel reticulated matrix 20.
The rotation angle parameter of multiple multi-pore channel reticulated matrix 20 is expressed as [0:m:n], wherein 0 indicates more with first layer
On the basis of duct reticulated matrix 20, the angle of first layer multi-pore channel reticulated matrix 20 is 0 °；M is the N+1 layers of netted base of multi-pore channel
The angle that body 20 is rotated relative to n-th layer multi-pore channel reticulated matrix 20；N be the last layer multi-pore channel reticulated matrix 20 relative to
The angle that first layer multi-pore channel reticulated matrix 20 is rotated, the number of multi-pore channel reticulated matrix 20 are (n/m)+1.As n=0,
The number of multi-pore channel reticulated matrix 20 is two layers, and second layer multi-pore channel reticulated matrix 20 is relative to first layer multi-pore channel reticulated matrix
20 m ° of rotations.
Such as a kind of embodiment, the rotation angle parameter of multi-pore channel reticulated matrix 20 is expressed as [0:9:81], refers to porous
Road reticulated matrix 20 is 9 ° relative to the rotation angle of upper layer multi-pore channel reticulated matrix 20, and the number of multi-pore channel reticulated matrix 20 is
10.According to another embodiment, the technical parameter of multi-pore channel reticulated matrix 20 is expressed as [0:180], refers to that multi-pore channel is netted
Matrix 20 has rotated 180 ° relative to upper layer multi-pore channel reticulated matrix 20, and the number of multi-pore channel reticulated matrix 20 is 2.
Emphasis illustrates cable 23 and the specific specification of sieve pore 22 below.
The shape of the cross section of sieve pore 22 is square, rectangle, triangle, polygon, circle, parallelogram, ladder
One of shape is a variety of.In the utility model, as shown in Fig. 6, the rugosity D of cable 23 is 10~500 μm, preferably 20
~200 μm, further preferably 20 μm~50 μm, more preferably 40 μm~50 μm.
In the utility model, cable 23 with a thickness of 10~500 μm, preferably 20~200 μm, further preferably 20 μm
~50 μm, more preferably 40 μm~50 μm.
The cross-sectional area of sieve pore 22 is 10~6000 μm2, preferably 20~3000 μm2, further preferably 700~
3000μm2, more preferably 700~2000 μm2。
The spacing of adjacent two layers multi-pore channel reticulated matrix 20 is 0.1~10mm, preferably 0.5~1.5mm.
In order to specifically bind with target cell or biomolecule 3, trapping layer includes can be with target cell or life
The catches 21 that object molecule 3 is specifically bound.Specifically, catches 21 is bonded to netted by physical absorption and/or chemical bonded refractory
On matrix.Preferably, catches 21 is connected by using traut ' s reagent or the mercaptan molecules of salt with biotin-avidin
To reticulated matrix.As shown in Fig. 5, catches 21 can be specifically bound with target cell or biomolecule 3.
Catches 21 is the specific antibody or other kinds of for target cell or target molecule in the utility model
Specific recognition molecules, the target molecule that the catches is directed to are selected from one of following multiple types or a variety of:
EpCAM, EphB4, EGFR, HER2, HER-2/neu, MUC-1, folacin receptor, AFP, CEA, Cyfra21-1, TPA, TPS,
NMP22, β 2-MG, thyroglobulin, ferritin, CA19-9, CA125, CA50, CA72-4, CA242, CA15-3, SCC,
LDH, NSE, PSA, ER, progesterone receptor, HCG, β-hCG, prolactin, ACTH, calcitonin, ras gene, P53, myc- gene,
DHEA-S, cortisol, aldosterone, uPA/PAI-1, serotonin, 5-hydroxyindoleacetic acid, HGH, FSH, LH, TSH, paraprotein, chest
Gland pyrimidine kinases, neopterin, SEA, Protein S -100, M2-PK, Chromogranin A, bone-specific alkaline phosphatase, deoxidation pyridine
Quinoline, CASA, adrenaline substance, catecholamine, homovanillic acid, adrenin, vanillylmandelic acid (VMA), f-PSA, PCA3,
AFP, P-ALP, calcitonin, gastrin, TSA, AFU, γ GT, ALP, CA549, PAP, bence-Jones protein.
The target cell or biomolecule 3 that different catches 21 can be specifically bound are as shown in the table.
In order to improve capture rate and increase the specificity of multi-pore channel reticulated matrix 20, the utility model can also be set
The catches 21 set in enrichment isolation mechanism on two layers of multi-pore channel reticulated matrix 20 is different, can also be with three layers of multi-pore channel reticulated matrix
Catches 21 on 20 is different.Preferably, the catches 21 on every layer of multi-pore channel reticulated matrix 20 is different.
In the utility model, catches 21 in enrichment isolation mechanism at least two layers of multi-pore channel reticulated matrix 20 respectively with
Same target cell or biomolecule 3 are specifically bound；Preferably, the catches 21 on three layers of multi-pore channel reticulated matrix 20 divides
It is not specifically bound with same target cell or biomolecule 3；It is further preferred that on four layers of multi-pore channel reticulated matrix 20
Catches 21 specifically bound respectively with same target cell or biomolecule 3；Most preferably, every layer of multi-pore channel is netted
Catches 21 on matrix 20 is specifically bound with same target cell or biomolecule 3 respectively.
According to a kind of embodiment, multi-pore channel reticulated matrix 20 is 5, and the capture on each multi-pore channel reticulated matrix 20
Object 21 is different, and five layers of catches 21 is respectively that can specifically bind EphB4, EGFR, HER2, CEA and ferritin
(ferritin) antibody, this five kinds of catches 21 are specifically bound with same target cell, that is, breast cancer tumor cells.
In the utility model, target cell or biomolecule 3, Duo Geduo not of the same race can be disposably screened in order to realize
The catches 21 and a kind of target cell or biomolecule 3 of at least one multi-pore channel reticulated matrix 20 of duct reticulated matrix 20 are special
The opposite sex combines, and the catches 21 of at least another multi-pore channel reticulated matrix 20 and another target cell or biomolecule 3 are specifically
Property combine.Preferably, the catches 21 of each multi-pore channel reticulated matrix 20 is special from different target cells or biomolecule 3 respectively
The opposite sex combines.
According to another embodiment, multi-pore channel reticulated matrix 20 is 10, and on each multi-pore channel reticulated matrix 20
Catches 21 is different, and the target molecule 3 that 10 layers of catches 21 is specifically bound is listed below respectively: HER-2/neu (blood
Clearly, organize)-breast cancer；Folacin receptor (FR)-lung cancer；NMP22 (urine)-bladder cancer；Prolactin (PRL)-hypophysoma；DHEA-S-
Adrenal cortex；Serotonin (5-HT)-class cancer；Protein S -100- melanoma；M2-PK- kidney；Chromogranin A
(chromograninA, CGA)-neuroendocrine tumors；PAP- prostate cancer.10 kinds of different catches 21 respectively tie by specificity
It closes 10 kinds of different target molecules or is integrated on different targeted cell surfaces (when there is expression on the outer surface of target cell
Target molecule).
Embodiment 1
Multi-pore channel reticulated matrix 20 10 in total, it is 0 ° that 10 multi-pore channel reticulated matrix 20, which are arranged in parallel and rotate angle,
The spacing of adjacent porous road reticulated matrix 20 is 1mm, and cable 23 is 44 μm with a thickness of 44 μm, rugosity, the cross section of sieve pore 22
Product is 27 × 27 μm2。
The catches connected on first multi-pore channel reticulated matrix 20 is EpCAM antibody, second multi-pore channel reticulated matrix
The catches connected on 20 is EphB4 antibody, and the catches connected on third multi-pore channel reticulated matrix 20 is EGFR antibody, the
The catches connected on four multi-pore channel reticulated matrix 20 is HER2 antibody, and what is connected on the 5th multi-pore channel reticulated matrix 20 catches
Obtaining object is MUC-1 antibody, and the catches on the 6th multi-pore channel reticulated matrix 20 is CEA antibody, the 7th netted base of multi-pore channel
Catches on body 20 is ferritin antibody, and the catches on the 8th multi-pore channel reticulated matrix 20 is CA15-3 antibody, the 9th
Catches on a multi-pore channel reticulated matrix 20 is ER antibody, and the catches on the tenth multi-pore channel reticulated matrix 20 is progestational hormone
Receptor antibody.The method that catches is connected on each multi-pore channel reticulated matrix 20 is identical, below with first netted base of multi-pore channel
For body 20, it is described in detail.
The method that catches is connected on multi-pore channel reticulated matrix 20 includes the following steps:
(1) 4.6 microlitres of Traut ' s reagent solution (0.2 mg/ml), 5 microlitres of EPCAM antibody (Cat# are taken
Ab32392, Abcam), 40.4 microlitres of PBS-EDTA (2.5 mMs, pH8.0) are simultaneously incubated at room temperature one after mixing three
Hour.
(2) solution after incubation acquired in step 1 is added dropwise on multi-pore channel reticulated matrix 20, is incubated at room temperature one
Hour.
(3) after 1 milliliter of PBS solution rinse being added to multi-pore channel reticulated matrix 20, residual solution is sucked.
(4) step 3 is repeated.
(5) to multi-pore channel reticulated matrix 20 be added 1 milliliter of 2%BSA solution (account for BSA solution gross mass 2% BSA and
Account for the PBS solution of BSA solution gross mass 98%), it is then incubated at room temperature 30 minutes.
6) multi-pore channel reticulated matrix 20 is fixed in the cavity of main body.
The method of capture circulating tumor cell includes the following steps:
(1) in the cell suspending liquid injection enrichment isolation mechanism by 0.5mL containing 10 breast cancer cells；
(2) so that the cell suspending liquid of 0.5mL is flowed through the entrance 11 of enrichment isolation mechanism, speed is 7.8 × 10-5M/s, cell
Suspension flows successively through 10 layers of multi-pore channel reticulated matrix 20, so that breast cancer cell is incorporated in enrichment isolation mechanism；
(3) 0.5 milliliter of PBS solution is added, cleans multi-pore channel reticulated matrix 20 with 100 microlitres of speed per minute, removal is not
In conjunction with sundries, cell or molecule；
(4) multi-pore channel reticulated matrix 20 is removed, and the multi-pore channel reticulated matrix 20 removed is placed in 0.5mL eluent, and (pancreatin accounts for
The PBS solution of eluent gross mass 0.25%, 1mM EDTA and surplus) in, it is incubated for 2 minutes at 37 DEG C, then shakes 10
Second so that breast cancer cell is separated from enrichment isolation mechanism；
(5) 0.5mL neutralizer (fetal calf serum) is added, takes out multi-pore channel reticulated matrix 20, be centrifuged 5 minutes with 300g speed,
It after sucking supernatant, after being resuspended using PBS or cell culture fluid and is counted, the breast cancer cell number of retention is 6.
Embodiment 2:
It is substantially the same manner as Example 1, the difference is that: the angle rotation parameter of multiple multi-pore channel reticulated matrix 20 is
[0:36:324], i.e. lower layer's multi-pore channel reticulated matrix 20 are 36 ° relative to the angle that upper layer multi-pore channel reticulated matrix 20 rotates.
Cable 23 is 22 μm with a thickness of 22 μm, rugosity, and the cross-sectional area of sieve pore 22 is 54 × 54 μm2。
The breast cancer cell of embodiment retention is 7.
Embodiment 3:
It is substantially the same manner as Example 1, the difference is that: the angle rotation parameter of multiple multi-pore channel reticulated matrix 20 is
[0:9:81], i.e. lower layer's multi-pore channel reticulated matrix 20 are 9 ° relative to the angle that upper layer multi-pore channel reticulated matrix 20 rotates.
Cable 23 is 22 μm with a thickness of 22 μm, rugosity, and the cross-sectional area of sieve pore 22 is 54 × 54 μm2。
The breast cancer cell number of embodiment retention is 5.
Embodiment 4:
It is substantially the same manner as Example 1, the difference is that: multi-pore channel reticulated matrix 20 2 in total, multiple multi-pore channels are netted
The angle rotation parameter of matrix 20 is [0:180], i.e., lower layer's multi-pore channel reticulated matrix 20 is relative to upper layer multi-pore channel reticulated matrix
The angle of 20 rotations is 180 °.
Cable 23 is 22 μm with a thickness of 22 μm, rugosity, and the cross-sectional area of sieve pore 22 is 54 × 54 μm2。
The catches connected on first multi-pore channel reticulated matrix 20 is EpCAM antibody, second multi-pore channel reticulated matrix
The catches connected on 20 is EphB4 antibody.
The breast cancer cell number of embodiment retention is 2.
Embodiment 5:
It is substantially the same manner as Example 1, the difference is that: multi-pore channel reticulated matrix 20 5 in total, multiple multi-pore channels are netted
The angle rotation parameter of matrix 20 is [0:60:240], i.e., lower layer's multi-pore channel reticulated matrix 20 is relative to the netted base of upper layer multi-pore channel
The angle that body 20 rotates is 60 °.
Cable 23 is 22 μm with a thickness of 22 μm, rugosity, and the cross-sectional area of sieve pore 22 is 54 × 54 μm2。
The catches connected on first multi-pore channel reticulated matrix 20 is EpCAM antibody, second multi-pore channel reticulated matrix
The catches connected on 20 is EphB4 antibody, and the catches connected on third multi-pore channel reticulated matrix 20 is EGFR antibody, the
The catches connected on four multi-pore channel reticulated matrix 20 is HER2 antibody, and what is connected on the 5th multi-pore channel reticulated matrix 20 catches
Obtaining object is MUC-1 antibody.
The breast cancer cell number of embodiment retention is 4.
Embodiment 6:
It is substantially the same manner as Example 1, the difference is that: multi-pore channel reticulated matrix 20 5 in total, multiple multi-pore channels are netted
The angle rotation parameter of matrix 20 is [0:60:240], i.e., lower layer's multi-pore channel reticulated matrix 20 is relative to the netted base of upper layer multi-pore channel
The angle that body 20 rotates is 60 °.
The cross-sectional area of sieve pore 22 is 54 × 54 μm2。
The catches connected on first multi-pore channel reticulated matrix 20 is EpCAM antibody, second multi-pore channel reticulated matrix
The catches connected on 20 is EphB4 antibody, and the catches connected on third multi-pore channel reticulated matrix 20 is EGFR antibody, the
The catches connected on four multi-pore channel reticulated matrix 20 is HER2 antibody, and what is connected on the 5th multi-pore channel reticulated matrix 20 catches
Obtaining object is MUC-1 antibody.
The breast cancer cell number of embodiment retention is 7.
Embodiment 7:
It is substantially the same manner as Example 1, the difference is that: multi-pore channel reticulated matrix 20 5 in total, multiple multi-pore channels are netted
The angle rotation parameter of matrix 20 is [0:60:240], i.e., lower layer's multi-pore channel reticulated matrix 20 is relative to the netted base of upper layer multi-pore channel
The angle that body 20 rotates is 60 °.
Cable 23 is 22 μm with a thickness of 22 μm, rugosity.
The catches connected on first multi-pore channel reticulated matrix 20 is EpCAM antibody, second multi-pore channel reticulated matrix
The catches connected on 20 is EphB4 antibody, and the catches connected on third multi-pore channel reticulated matrix 20 is EGFR antibody, the
The catches connected on four multi-pore channel reticulated matrix 20 is HER2 antibody, and what is connected on the 5th multi-pore channel reticulated matrix 20 catches
Obtaining object is MUC-1 antibody.
The breast cancer cell number of embodiment retention is 6.
Embodiment 8:
It is substantially the same manner as Example 1, the difference is that: multi-pore channel reticulated matrix 20 5 in total, multiple multi-pore channels are netted
The angle rotation parameter of matrix 20 is [0:60:240], i.e., lower layer's multi-pore channel reticulated matrix 20 is relative to the netted base of upper layer multi-pore channel
The angle that body 20 rotates is 60 °.
The catches connected on first multi-pore channel reticulated matrix 20 is EpCAM antibody, second multi-pore channel reticulated matrix
The catches connected on 20 is EphB4 antibody, and the catches connected on third multi-pore channel reticulated matrix 20 is EGFR antibody, the
The catches connected on four multi-pore channel reticulated matrix 20 is HER2 antibody, and what is connected on the 5th multi-pore channel reticulated matrix 20 catches
Obtaining object is MUC-1 antibody.
The breast cancer cell number of embodiment retention is 10.
Embodiment 9:
It is substantially the same manner as Example 1, the difference is that: the angle rotation parameter of multiple multi-pore channel reticulated matrix 20 is
[0:36:324], i.e. lower layer's multi-pore channel reticulated matrix 20 are 36 ° relative to the angle that upper layer multi-pore channel reticulated matrix 20 rotates.
The breast cancer cell number of embodiment retention is 10.
Embodiment 10
It is substantially the same manner as Example 9, the difference is that: the circumradius of the square sieve pore 22 in cross section is 27
μm。
The lung carcinoma cell number of embodiment retention is 10.
Embodiment 11
It is substantially the same manner as Example 9, the difference is that: the cross section of sieve pore 22 is triangular in shape, and circumradius is
27μm。
The lung carcinoma cell number of embodiment retention is 10.
Embodiment 12
It is substantially the same manner as Example 9, the difference is that: the cross section of sieve pore 22 is hexagonal, and circumradius is
27μm。
The lung carcinoma cell number of embodiment retention is 10.
Embodiment 13
The angle rotation parameter of multiple multi-pore channel reticulated matrix 20 is [0:36:324], i.e. lower layer's multi-pore channel reticulated matrix 20
The angle rotated relative to upper layer multi-pore channel reticulated matrix 20 is 36 °, multi-pore channel reticulated matrix 20 a total of 10.
The spacing of adjacent porous road reticulated matrix 20 is 1mm, and cable 23 is 44 μm with a thickness of 44 μm, rugosity, sieve pore 22
Cross section it is square, the cross-sectional area of sieve pore 22 is 27 × 27 μm2。
The catches connected on first multi-pore channel reticulated matrix 20 is EphB4 antibody, second multi-pore channel reticulated matrix
The catches connected on 20 is folacin receptor antibody, and the catches connected on third multi-pore channel reticulated matrix 20 is AFP antibody,
The catches connected on 4th multi-pore channel reticulated matrix 20 is NMP22 antibody, is connected on the 5th multi-pore channel reticulated matrix 20
Catches be β 2-MG antibody, the catches on the 6th multi-pore channel reticulated matrix 20 is thyroglobulin antibody, the 7th
Catches on multi-pore channel reticulated matrix 20 is PSA antibody, and the catches on the 8th multi-pore channel reticulated matrix 20 is prolactin
Antibody, the catches on the 9th multi-pore channel reticulated matrix 20 are -100 antibody of Protein S, on the tenth multi-pore channel reticulated matrix 20
Catches be bence-Jones protein antibody.Catches is connected to method and the basic phase of embodiment 1 on multi-pore channel reticulated matrix 20
Together, the difference is that, catches is substituted for corresponding catches.
The method of capture circulating tumor cell includes the following steps:
(1) 5mL is contained to 10 breast cancer cells, 10 lung carcinoma cells, 10 liver cancer cells, 10 bladder cancer cells, 10 respectively
A lymph/granulocytic leukemia cell, 10 thyroid carcinoma cells, 10 prostate gland cancer cells, 10 pituitary tumor cells, 10
In melanoma cells, the cell suspending liquid injection enrichment isolation mechanism of 10 myeloma cells；
(2) so that cell suspending liquid is flowed through the entrance 11 of enrichment isolation mechanism, speed is 7.8 × 10-5M/s, cell suspending liquid according to
It is secondary to flow through 10 layers of multi-pore channel reticulated matrix 20, it is incorporated in target cell in enrichment isolation mechanism；
(3) 0.5 milliliter of PBS solution is added, cleans multi-pore channel reticulated matrix 20 with 100 microlitres of speed per minute, removal is not
In conjunction with sundries, cell or molecule；
(4) 10 multi-pore channel reticulated matrix 20 are dismantled, the multi-pore channel reticulated matrix 20 removed is placed in 0.5mL eluent
In (PBS solution that pancreatin accounts for eluent gross mass 0.25%, 1mM EDTA and surplus), it is incubated for 2 minutes at 37 DEG C, then
Concussion 10 seconds so that target cell is separated from enrichment isolation mechanism；
(5) 0.5mL neutralizer (fetal calf serum) is added, takes out multi-pore channel reticulated matrix 20, be centrifuged 5 minutes with 300g speed,
It after sucking supernatant, after cell precipitation is resuspended using PBS or cell culture fluid and counts, the breast cancer cell of retention
Number is 3, and the lung carcinoma cell number of retention is 4, and the liver cancer cells number of retention is 7, and the bladder cancer cell number of retention is 6,
The lymph of retention/granulocytic leukemia cell number is 4, and the thyroid carcinoma cell number of retention is 6, and the prostate cancer of retention is thin
Born of the same parents' number is 6, and the pituitary tumor cell number of retention is 4, and the melanoma cells number of retention is 5, the myeloma cell of retention
Number is 7.
Embodiment 14
The angle rotation parameter of multiple multi-pore channel reticulated matrix 20 is [0:36:324], i.e. lower layer's multi-pore channel reticulated matrix 20
The angle rotated relative to upper layer multi-pore channel reticulated matrix 20 is 36 °, multi-pore channel reticulated matrix 20 a total of 10.
The spacing of adjacent porous road reticulated matrix 20 is 1mm, and cable 23 is 44 μm with a thickness of 44 μm, rugosity, sieve pore 22
Cross section it is square, the cross-sectional area of sieve pore 22 is 27 × 27 μm2。
The catches connected on first multi-pore channel reticulated matrix 20 is folacin receptor antibody, second netted base of multi-pore channel
The catches connected on body 20 is folacin receptor antibody, the catches connected on third multi-pore channel reticulated matrix 20 for folic acid by
Body antibody, the catches connected on the 4th multi-pore channel reticulated matrix 20 are folacin receptor antibody, the 5th netted base of multi-pore channel
The catches connected on body 20 is DHEA-S antibody, and the catches on the 6th multi-pore channel reticulated matrix 20 is anti-for serotonin
Body, the catches on the 7th multi-pore channel reticulated matrix 20 are -100 antibody of Protein S, on the 8th multi-pore channel reticulated matrix 20
Catches is M2-PK antibody, and the catches on the 9th multi-pore channel reticulated matrix 20 is Chromogranin A antibody, more than the tenth
Catches on duct reticulated matrix 20 is PAP antibody.
The method of capture circulating tumor cell includes the following steps:
(1) 5mL is contained respectively 40 lung carcinoma cells, 10 adrenocortical carcinoma cells, 10 class cancer cancer cells, 10 it is black
Melanoma cancer cell, 10 kidney cancer cells, 10 neuroendocrine oncocytes, 10 prostate gland cancer cells cell suspending liquid note
Enter in enrichment isolation mechanism；
(2) so that cell suspending liquid is flowed through the entrance 11 of enrichment isolation mechanism, speed is 7.8 × 10-5M/s, cell suspending liquid according to
It is secondary to flow through 10 layers of multi-pore channel reticulated matrix 20, so that target cell is incorporated in enrichment isolation mechanism；
(3) 0.5 milliliter of PBS solution is added, cleans multi-pore channel reticulated matrix 20 with 100 microlitres of speed per minute, removal is not
In conjunction with sundries, cell or molecule；
(4) multi-pore channel reticulated matrix 20 is removed, and the multi-pore channel reticulated matrix 20 removed is placed in 0.5mL eluent, and (pancreatin accounts for
The PBS solution of eluent gross mass 0.25%, 1mM EDTA and surplus) in, it is incubated for 2 minutes at 37 DEG C, then shakes 10
Second so that target cell is separated from enrichment isolation mechanism；
(5) 0.5mL neutralizer (fetal calf serum) is added, takes out multi-pore channel reticulated matrix 20, be centrifuged 5 minutes with 300g speed,
It after sucking supernatant, after being resuspended using PBS or cell culture fluid and is counted, the lung carcinoma cell of retention is 36, retention
Adrenocortical carcinoma cells be 5, the class cancer cancer cell of retention is 4, and the melanoma cancer cells of retention are 3, retention
Kidney cancer cell be 5, the neuroendocrine oncocyte of retention is 3, and the prostate gland cancer cell number of retention is 2.
As described above, we are illustrated fully according to the objective of the utility model, but the utility model not limits to
In above-described embodiment and implementation method.The range that the practitioner of correlative technology field can permit in the technical idea of the utility model
It is interior to carry out different variation and implementation.
Claims (11)
1. a kind of for capturing the enrichment isolation mechanism of target cell or biomolecule, including multiple multi-pore channel nets disposed in parallel
Shape matrix (20), the multi-pore channel reticulated matrix (20) include formed by the cable (23) of a plurality of setting that intersects it is netted
It matrix, the multiple sieve pores (22) formed by the cable (23) of a plurality of setting that intersects and is fixedly attached to described
Reticulated matrix on trapping layer, the trapping layer includes that can specifically bind with target cell or biomolecule (3)
Catches (21), it is characterised in that: the catches (21) on multi-pore channel reticulated matrix (20) described at least two layers is different.
2. enrichment isolation mechanism according to claim 1, it is characterised in that: multi-pore channel reticulated matrix (20) described in every layer
On catches (21) it is different.
3. enrichment isolation mechanism according to claim 1, it is characterised in that: multi-pore channel reticulated matrix described at least two layers
(20) catches (21) on is specifically bound with same target cell or biomolecule (3) respectively.
4. enrichment isolation mechanism according to claim 1, it is characterised in that: multiple multi-pore channel reticulated matrix (20)
At least one multi-pore channel reticulated matrix (20) catches (21) and a kind of target cell or biomolecule (3) specificity tie
It closes, the catches (21) of at least another multi-pore channel reticulated matrix (20) and another target cell or biomolecule (3) are specifically
Property combine.
5. enrichment isolation mechanism according to claim 1, it is characterised in that: multi-pore channel reticulated matrix described in adjacent two layers
(20) sieve pore (22) is partially arranged in a staggered manner.
6. enrichment isolation mechanism according to claim 5, it is characterised in that: multi-pore channel reticulated matrix described in adjacent two layers
(20) lower layer's multi-pore channel reticulated matrix (20) rotates 5 ~ 180 ° relative to upper layer multi-pore channel reticulated matrix (20) in.
7. enrichment isolation mechanism according to claim 6, it is characterised in that: each multi-pore channel reticulated matrix (20)
The direction of rotation of opposite upper layer multi-pore channel reticulated matrix (20) is consistent.
8. enrichment isolation mechanism according to claim 6, it is characterised in that: each multi-pore channel reticulated matrix (20)
Rotation angle relative to upper layer multi-pore channel reticulated matrix (20) is identical.
9. enrichment isolation mechanism according to claim 1, it is characterised in that: the rugosity of the cable (23) be 10 μm ~
500 μm, the cable (23) with a thickness of 10 μm ~ 500 μm, the cross-sectional area of the sieve pore (22) is 10 ~ 6000 μ
M2, the spacing of multi-pore channel reticulated matrix (20) described in adjacent two layers are 0.1 ~ 10mm.
10. enrichment isolation mechanism according to claim 1, it is characterised in that: the multi-pore channel reticulated matrix (20)
Number is 2 ~ 30.
11. enrichment isolation mechanism according to claim 1, it is characterised in that: the shape of the cross section of the sieve pore (22)
Shape is square, rectangle, triangle, polygon, circle, parallelogram, trapezoidal one or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201820848148.4U CN208717302U (en) | 2018-05-25 | 2018-05-25 | For capturing the enrichment isolation mechanism of target cell or biomolecule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201820848148.4U CN208717302U (en) | 2018-05-25 | 2018-05-25 | For capturing the enrichment isolation mechanism of target cell or biomolecule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN208717302U true CN208717302U (en) | 2019-04-09 |
Family
ID=65971173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201820848148.4U Active CN208717302U (en) | 2018-05-25 | 2018-05-25 | For capturing the enrichment isolation mechanism of target cell or biomolecule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN208717302U (en) |
-
2018
- 2018-05-25 CN CN201820848148.4U patent/CN208717302U/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108753569A (en) | A kind of enrichment isolation mechanism for capturing cell or biomolecule | |
| Esmaeilsabzali et al. | Detection and isolation of circulating tumor cells: principles and methods | |
| US9140697B2 (en) | Device for capturing circulating cells | |
| CN102822676B (en) | Methods for predicting response of triple-negative breast cancer to therapy | |
| US10350599B2 (en) | Non-invasive monitoring cancer using integrated microfluidic profiling of circulating microvesicles | |
| CN103756967B (en) | Application of the monoclonal antibody coupling immunomagnetic beads of anti-HLA-G in tumour cell sorting | |
| CN103642755B (en) | The method separating circulating tumor cell from blood | |
| CN107356744B (en) | Method for sorting and/or enriching circulating tumor cells and kit thereof | |
| MX2014006884A (en) | Apparatus, system and method for identifying circulating tumor cells. | |
| JP2015523559A (en) | Capture, identification and use of new biomarkers of solid tumors in body fluids | |
| CN107109477A (en) | Application and its separation method of the circulating cells biomarker in blood in detecting and diagnosing the illness | |
| CN109874316A (en) | For enrichment isolation the object such as cell, bacterium or the device of biomolecule from sample | |
| EP3765853B1 (en) | Methods for monitoring treatment response and disease progression in subjects using circulating cells | |
| CN105087493A (en) | Joint application of three types of monoclonal antibody-coupled immunomagnetic beads to sorting tumor cells | |
| Zhou et al. | Nanoparticle modification of microfluidic cell separation for cancer cell detection and isolation | |
| CN208362321U (en) | It is a kind of for capturing the enrichment isolation mechanism of target cell or biomolecule | |
| CN107817340A (en) | A kind of kit of SERS technology for detection Mdr-p and its application | |
| CN208717302U (en) | For capturing the enrichment isolation mechanism of target cell or biomolecule | |
| JP2021536563A (en) | Uniform assay method with particle agglutination or deagglomeration | |
| CN109557296B (en) | Method for circularly detecting drug sensitivity of tumor cells | |
| Zhao et al. | Separation and single-cell analysis for free gastric cancer cells in ascites and peritoneal lavages based on microfluidic chips | |
| CN108707577A (en) | The elution process and catching method of a kind of cell or biomolecule | |
| CN209555255U (en) | A kind of kit early sieved for three-dimensional noninvasive tumour | |
| CN107213927A (en) | A kind of micro-fluidic chip of high flux illicit drugs inspection and application | |
| CN104535772B (en) | Polypeptide-magnetic nanoparticle of the circulating tumor cell of HER2 high expressed and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 215301 4 / F and 5 / F, room 12, No. 1798, West zhonghuayuan Road, Yushan Town, Kunshan City, Suzhou City, Jiangsu Province Patentee after: Jiangsu Huixian Pharmaceutical Technology Co.,Ltd. Address before: 215300 Pilot Building 101, No. 168 Yuanfeng Road, Yushan Town, Kunshan City, Suzhou City, Jiangsu Province Patentee before: KUNSHAN HUIXIAN MEDICAL TECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 215301 4 / F and 5 / F, room 12, No. 1798, West zhonghuayuan Road, Yushan Town, Kunshan City, Suzhou City, Jiangsu Province Patentee after: Jiangsu Huixian Pharmaceutical Technology Co.,Ltd. Address before: 215300 Pilot Building 101, No. 168 Yuanfeng Road, Yushan Town, Kunshan City, Suzhou City, Jiangsu Province Patentee before: KUNSHAN HUIXIAN MEDICAL TECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address |